Emergent BioSolutions Announces Stock Repurchase Program

Core Viewpoint - Emergent BioSolutions Inc. has authorized a stock repurchase program of up to $50 million, reflecting confidence in its strategy and future outlook while aiming to create long-term value for shareholders [1][2]. Company Overview - Emergent BioSolutions has approximately 54.3 million shares of common stock outstanding as of December 31, 2024 [3]. - The company focuses on delivering protective and life-saving solutions for various health threats, including smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies [4]. Stock Repurchase Program - The stock repurchase may occur on the open market or through privately negotiated transactions, with timing and amount determined by management based on market conditions and other factors [2]. - The program is part of the company's multi-year transformation plan aimed at driving long-term growth and profitability [2].